Ozempic is not insulin: what its label says it is

What the label says Ozempic is

The first line of the Ozempic label’s highlights names the class: “OZEMPIC is a glucagon-like peptide 1 (GLP-1) receptor agonist”, indicated “as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus”. Insulin appears nowhere in it.

What the drug does with insulin is in section 7.1, in one line: “OZEMPIC stimulates insulin release in the presence of elevated blood glucose concentrations.” The insulin is yours. Section 12.1 adds the qualifier that matters: semaglutide stimulates insulin secretion and lowers glucagon secretion “both in a glucose-dependent manner”, so “when blood glucose is high, insulin secretion is stimulated, and glucagon secretion is inhibited.” An injection of insulin does not wait to be asked.

That difference runs through the rest of the label. How the drug works in full is on how GLP-1 drugs work.

Insulin is on the same label, as a different drug

Insulin is all over these four labels, always as a separate drug the patient may already be taking.

Read that column again and the answer is plain: a drug that replaced insulin would not need a warning about taking insulin with it. Which diabetes medicines each label flags, and what it says to do about them, is on the drug interactions page.

Is tirzepatide a GLP-1?

Yes, and one more besides. Both tirzepatide labels open with the same description: Mounjaro is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist, and Zepbound’s section 1 says the same of it. So tirzepatide is a GLP-1 receptor agonist, and it acts on a second receptor as well, for a hormone called glucose-dependent insulinotropic polypeptide.

That matters for a practical reason: both weight-loss labels tell you not to stack them. Zepbound’s limitation of use reads “Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended”, and Wegovy prints the same rule for semaglutide-containing products. Two of these drugs at once is not two treatments.

Why the mix-up matters when you are reading a price

“GLP-1” is a class, not a product. A seller advertising a monthly price for a GLP-1 may be pricing semaglutide, tirzepatide, an injection, a tablet, a branded pen or a compounded vial, and those are different things with different labels behind them. Of the published prices read for this site, many never name a drug at all.

None of them is insulin. If a page offers you insulin and a GLP-1 in the same sentence, the labels above say those are two prescriptions, not one, and that taking both is a conversation with a prescriber rather than a checkout choice.

Sources

See the providers

What a seller dispenses is a property of its prescription, not of its marketing. The boards list who sells each molecule and what each one publishes.

• Semaglutide providersprovider board

  Readers who have settled on semaglutide and are choosing who to buy it from.

• Tirzepatide providersprovider board

  Readers who have settled on tirzepatide and are choosing who to buy it from.

More, read from the same labels

• Semaglutide vs tirzepatidereading the label

  What the four FDA-approved labels say each molecule is, what each is approved to treat, and where the two differ.

• How they workreading the label

  The receptor each molecule switches on, what the labels say that does to appetite, blood sugar and the stomach, and why one dose lasts a week.

• Zepbound vs Ozempicreading the label

  Four brand names, two molecules and two kinds of approval: which of these products are the same drug, and what each one is actually approved to do.

• Dose escalation schedulesreading the label

  The starting dose, the escalation interval and the maximum dose each label sets, and why they are not interchangeable.

• Side effect ratesreading the label

  What each label reports for nausea, vomiting, diarrhea and constipation — and the sentence every label prints above those numbers.

• Hair lossreading the label

  Which labels report hair loss, the rate against placebo where a trial measured it, and why two of them put no number on it.

• Fatigue and tirednessreading the label

  Which labels list fatigue, the rate against placebo where a trial measured it, and what each label counts as fatigue.

• Missed dose rulesreading the label

  The window each label gives for a late dose, and the minimum gap it requires when the injection day changes.

• Drug interactionsreading the label

  Insulin and sulfonylureas, oral medications, and the oral-contraceptive precaution that appears on two of these four labels and not the other two.

• Buying one onlinereading the label

  The agency's own warning signs for a telehealth GLP-1 seller, its 28-day vial rule, and what it says about drugs that arrive warm.

• Zepbound by dosereading the label

  What each Zepbound dose achieved in the trials printed in its label, what the label says about choosing a maintenance dose, and what the higher doses cost in side effects.

• Zepbound at 3 monthsreading the label

  What the Zepbound label reports and at which weeks it reports it, and where the label's own dose schedule puts a reader at three months.

• Injecting tirzepatidereading the label

  The injection sites, the rotation rule and the steps for the single-dose pen, the KwikPen and the vial and syringe, exactly as the FDA-approved Instructions for Use give them.

• Refrigeration and storagereading the label

  How cold each pen is kept, how many days it can spend at room temperature, and what the labels say about heat and freezing.

• Who should not take onereading the label

  The boxed warning every one of these labels carries, the two contraindications, and which warnings appear on which product.